JP2021524451A5 - - Google Patents

Info

Publication number
JP2021524451A5
JP2021524451A5 JP2020564553A JP2020564553A JP2021524451A5 JP 2021524451 A5 JP2021524451 A5 JP 2021524451A5 JP 2020564553 A JP2020564553 A JP 2020564553A JP 2020564553 A JP2020564553 A JP 2020564553A JP 2021524451 A5 JP2021524451 A5 JP 2021524451A5
Authority
JP
Japan
Prior art keywords
amino acid
polypeptide chain
seq
acid sequence
epitope
Prior art date
Application number
JP2020564553A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019222104A5 (https=
JP2021524451A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/032030 external-priority patent/WO2019222104A1/en
Publication of JP2021524451A publication Critical patent/JP2021524451A/ja
Publication of JP2021524451A5 publication Critical patent/JP2021524451A5/ja
Publication of JPWO2019222104A5 publication Critical patent/JPWO2019222104A5/ja
Pending legal-status Critical Current

Links

JP2020564553A 2018-05-18 2019-05-13 最適化済みgp41結合分子及びその使用 Pending JP2021524451A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862673462P 2018-05-18 2018-05-18
US62/673,462 2018-05-18
PCT/US2019/032030 WO2019222104A1 (en) 2018-05-18 2019-05-13 Optimized gp41-binding molecules and uses thereof

Publications (3)

Publication Number Publication Date
JP2021524451A JP2021524451A (ja) 2021-09-13
JP2021524451A5 true JP2021524451A5 (https=) 2022-05-16
JPWO2019222104A5 JPWO2019222104A5 (https=) 2022-05-16

Family

ID=68540936

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020564553A Pending JP2021524451A (ja) 2018-05-18 2019-05-13 最適化済みgp41結合分子及びその使用

Country Status (12)

Country Link
US (1) US20210246194A1 (https=)
EP (1) EP3794027A4 (https=)
JP (1) JP2021524451A (https=)
CN (1) CN112533945A (https=)
AU (1) AU2019269383A1 (https=)
BR (1) BR112020023432A2 (https=)
CA (1) CA3100398A1 (https=)
IL (1) IL278832A (https=)
MX (1) MX2020012309A (https=)
SG (1) SG11202011355QA (https=)
WO (1) WO2019222104A1 (https=)
ZA (1) ZA202007056B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3152235B1 (en) * 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
EA201790719A1 (ru) * 2014-09-26 2017-07-31 Макродженикс, Инк. Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
SG11202005557TA (en) * 2017-12-12 2020-07-29 Macrogenics Inc Bispecific cd 16-binding molecules and their use in the treatment of disease
CN111647078B (zh) * 2020-06-22 2022-04-26 中国医学科学院医学生物学研究所 一种抗hiv的单克隆抗体及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691730B2 (en) * 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
JP6676521B2 (ja) * 2013-03-14 2020-04-08 マクロジェニクス,インコーポレーテッド 二重特異性分子、薬学的組成物及びそれらの使用
WO2015013390A1 (en) * 2013-07-25 2015-01-29 Pincus Seth Anti-hiv dual specificity antibodies and methods of hiv treatment
UA116479C2 (uk) * 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP3152235B1 (en) * 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
EP3201227A4 (en) * 2014-09-29 2018-04-18 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
WO2016168758A1 (en) * 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
AU2016334051B2 (en) * 2015-10-06 2023-10-26 Alector Llc Anti-TREM2 antibodies and methods of use thereof
MX2018014950A (es) * 2016-06-07 2019-04-25 Macrogenics Inc Terapia de combinacion.

Similar Documents

Publication Publication Date Title
Ma et al. Bispecific antibodies: from research to clinical application
Hosseini et al. Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: recent advances and clinical trials
Riethmüller Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on
JP2021524451A5 (https=)
JP2020055858A5 (https=)
JP2023106433A5 (https=)
JP2020529410A5 (https=)
JP2021098732A5 (https=)
JP2020531438A5 (ja) Nkg2d、cd16、およびhla−eに結合するタンパク質
JP2021524267A5 (https=)
JP2021522162A5 (https=)
JP2019536430A5 (https=)
IL271325B2 (en) Guidance and navigation control proteins and method of making and using thereof
WO2019005641A1 (en) GUIDING AND NAVIGATION CONTROL PROTEINS AND METHODS OF PRODUCTION AND USE THEREOF
JP2016536322A5 (https=)
JP2018533371A5 (https=)
RU2016114504A (ru) Би- или полиспецифические полипептиды, связывающие поверхностные антигены иммунных эффекторных клеток и антигены hbv для лечения инфекций bv и ассоциированных с ними состояний
RU2007145419A (ru) Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
JPWO2020113164A5 (https=)
JPWO2020252366A5 (https=)
JPWO2021064137A5 (https=)
JPWO2019222104A5 (https=)
JPWO2020132291A5 (https=)
JPWO2020205875A5 (https=)
JPWO2023141713A5 (https=)